Satellos Bioscience Inc T.MSCL

Alternate Symbol(s): MSCLF

Healthcare Biotechnology

Satellos Bioscience Inc. is a Canada-based biotechnology company. The Company is engaged in developing new small molecule therapeutic approaches to improve the treatment of muscle diseases and disorders. The Company is focused on the research in muscle stem cell polarity into a proprietary discovery platform, called MyoReGenX, to identify degenerative muscle diseases where deficits in this process affect muscle regeneration and are amenable to therapeutic intervention. With this platform, the Company is building a pipeline of therapeutics to correct muscle stem cell polarity and promote the body’s innate muscle repair and regeneration process. The Company’s lead program is an oral, small molecule drug candidate in development as a potential disease-modifying treatment for Duchenne muscular dystrophy. It has wholly owned subsidiaries in Australia (Satellos Bioscience Australia Pty Ltd), in Canada (Amphotericin B Technologies, Inc.) and in Delaware, USA (Satellos Bioscience US, Inc.).

TSX:MSCL - Post by User

Satellos Bioscience Inc

<< Previous

Bullboard Posts

Next >>

Post by db2067on Jul 04, 2022 10:02am

180 Views

Post# 34798937

Defeat Duchenne Canada

https://musculardystrophynews.com/2022/06/16/defeat-duchenne-canada-grants-1m-dmd-treatment-research/ Defeat Duchenne Canada grant recipients for this year include Michael Rudnicki, PhD, director of the Regenerative Medicine Program at the Ottawa Hospital Research Institute, Ottawa, Ontario. He’s discovered a protein called Wnt7a that could become a DMD treatment candidate due to its ability to repair muscle damage. Rudnicki will work to deliver the protein via circulation to all bodily muscles. In particular, his team is investigating exosomes, small vesicles found naturally in human bodies and which carry information between cells. Through the project, titled “Systemic Delivery of Wnt7a for Treating Duchenne Muscular Dystrophy,” Rudnicki and his lab will engineer new versions of exosomes carrying Wnt7a for delivery to muscle cells. The hope is that the prospective therapy will stimulate the muscles’ own capacity for regeneration and growth, independent of the underlying mutation.

<< Previous

Bullboard Posts

Next >>

Rig Count Soars as Utilization Surpasses Industry Averages